The Pfizer Clinical Research Unit (PCRU) in Brussels is seeking healthy participants for a clinical trial of a study drug for the treatment of COVID-19
The purpose of this study is to learn about the effects of the investigational drug on the body and to test its safety and impact
Who may participate
This study is seeking healthy male and female participants. Participants must be healthy, meaning they will not have the condition for which this treatment is being developed and are in overall good health. You may not take part in this study if:
You are younger than 18 years or you weigh less than or equal to 45 kg or you are outside of the limits for Body Mass Index (16 - 32 kg/m2).
There are other requirements for participation in this study. Please read attentively the Informed Consent Document (ICD), more explanation will be provided by the study staff during the screening process.
Condition
Healthy
Age
18+
Sex
Male/female
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
What to expect
If this study may be a fit for you, you’ll be invited to a screening visit at our facility in Brussels, Belgium.
The study will last for about 11 weeks. You will stay in the PCRU for 4 treatment periods, with a total stay of 10 days and 9 nights in the PCRU (from Day -1 of Period 1 to Day 3 of Period 4). You will not leave the facility between the dosing periods and will remain in PCRU until the last day of the last period (Day 3 of Period 4). The follow-up phone call will take place approximately 28-35 days after the last administration of the study drug.
You will receive a fat breakfast before administration on Day 1 of Period 4. This high-fat breakfast will include whole milk, eggs, fried potatoes, and bread. In addition, you will choose between a beef or vegetarian burger. Depending on your choice, you will respectively receive butter or margarine. You will be served breakfast 30 minutes before administration of the study drug. You will be asked to eat everything that you are given within approximately 20 minutes. You will have to finish the breakfast at approximately 10 minutes before administration.
You will be screened within 28 days prior to the first dose of study intervention.
Throughout the study, staff will closely monitor your health status and collect data.
You will not personally derive any benefit from your participation in this study, but the results obtained could be very important for the development of medicines and treatments which will benefit other people.
How long is the study?
Approximately 11 weeks
Compensation
Up to € 2.640, plus travel fees